In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date:  Note: The FDA’s information is current as of Dec. 18.  1. Phytonadione injection — For select coagulation disorders. 2.…

A federal judge granted a temporary restraining order blocking the Department of Health and Human Services from launching its 340B Rebate Model Pilot Program, which was scheduled to begin Jan. 1, 2026. U.S. District Judge Lance Walker of the District…

The FDA has accepted a biologics license application from Inovio for a potential treatment for adults with recurrent respiratory papillomatosis. Although the application was filed under the accelerated approval pathway, the FDA said in its acceptance letter that Inovio did…

As regulatory pressure mounts and workforce shortages persist, Louisville, Ky.-based Baptist Health System is positioning pharmacy as a safeguard for medication access and a driver of system growth. On an episode of the “Becker’s Pharmacy Leadership Podcast,” Nilesh Desai, chief…

Here are eight recent drug shortages and discontinuations, according to the FDA’s drug supply databases:

CMS published plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s agreements with Eli Lilly and Novo Nordisk to apply most-favored-nation…

As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B Rebate Model pilot and Maximum Fair Price (MFP) covered entities (CEs) are entering a period where manual…

Becker’s asked pharmacy executives from hospitals and health systems across the U.S. to share how pharmacy c-suites will transform through 2030. The 11 executives featured in this article are all speaking at the Becker’s Healthcare Spring Chief Pharmacy Officer Summit,…

The FDA has approved Novo Nordisk’s pill version of Wegovy, making it the first oral GLP-1 receptor agonist therapy cleared for chronic weight management. The once-daily 25-milligram oral semaglutide is indicated to reduce excess body weight, maintain long-term weight loss…

Even as regulators are cracking down on pharmacy benefit managers, some payers have been leaning into their own businesses in 2025.  Here are six payer moves indicating growing PBM interest: 1. Independent Health’s PBM subsidiary, Pharmacy Benefit Dimensions, is one…